Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Myriad Genetics Q2 Adj. EPS $0.05 Beats $(0.01) Estimate, Sales $213.10M Beat $201.88M Estimate

Author: Benzinga Newsdesk | August 05, 2025 04:08pm
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.01) by 600 percent. This is unchanged from the same period last year. The company reported quarterly sales of $213.10 million which beat the analyst consensus estimate of $201.88 million by 5.56 percent. This is a 0.76 percent increase over sales of $211.50 million the same period last year.

Posted In: MYGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist